Yatai Group was owned by 1.553 billion yuan, and Changchun state-owned assets took the lead in restructuring.

2026-11-17 09:46:52

It is reported that on July 17, 2026, Yatai Group and its five pharmaceutical subsidiaries received a notice from Changchun Intermediate People's Court. Creditors applied for reorganization and pre-reorganization on the grounds that they could not pay off their due debts and obviously lacked solvency but had the value of reorganization. On July 28, the court decided to start the pre-reorganization and appointed the liquidation team of the company as the temporary administrator. On August 4, the court publicly recruited investors; On October 27, the pre-restructuring period was extended to January 28, 2027; on November 4, the above consortium was determined by the evaluation committee.

On November 16, Yatai Group signed the Restructuring Investment Agreement with the restructuring investors.

According to the agreement, Changchun City Development Investment Holding (Group) Co., Ltd. (Hereinafter referred to as "Changfa Group") and Changchun Xingtai Enterprise Management Co., Ltd. formed a consortium, with a total investment of 1.553 billion yuan, and transferred 1.419 billion shares of Yatai Group, accounting for 20.90% of the total equity after the transfer.

Among them, Changfa Group, as the leading investor, transferred 747 million shares at 1 yuan per share, accounting for 11%, paid 747 million yuan, and will acquire the controlling right of Yatai Group after the completion of the transaction. Through the newly established Changchun Taiqi, Changchun Xingtai transferred 672 million shares at 1.2 yuan per share, accounting for 9.9%, and paid 806 million yuan. Both shares are locked up for 36 months.

The announcement disclosed that the market reference price for the transfer of shares was the lower of the average price of 20, 60 and 120 trading days before the signing of the agreement, that is, 1.63 yuan per share, and the transfer prices of 1 yuan and 1.2 yuan were not less than 50% of the reference price.

Changfa Group is a wholly state-owned company in Changchun, 100% owned by Changchun SASAC, with a registered capital of 5.022 billion yuan. By the end of 2025, the company had total assets of 338.9 billion yuan and net assets of 143.1 billion yuan. At present, Changfa Group has directly held 6.22% of the shares of Yatai Group, which is a related party, and the source of funds is self-owned or self-raised.

According to the business plan, Changfa Group will integrate the company's pharmaceutical research and development, pharmaceutical manufacturing, drug number, invention patents and characteristic Chinese medicine resources, open up the supply chain from R & D, pharmaceuticals to Jilin Pharmacy retail stores, and timely inject high-quality emerging assets. The signing of the

agreement is not the same as the completion of the reorganization. The Company and its five pharmaceutical subsidiaries are still in the pre-reorganization stage, and the pre-reorganization period has been extended to January 28, 2027. There is significant uncertainty as to whether the court can accept the application for reorganization.

By the end of September 2026, the net assets of Yatai Group were-286 million yuan. If the net assets at the end of the annual report are still negative, or the court accepts the application for reorganisation, the shares of the Company will be subject to delisting risk warning; if the reorganisation fails, the Company will face the risk of being declared bankrupt and delisting.

It is reported that on July 17, 2026, Yatai Group and five pharmaceutical subsidiaries received a notice from Changchun Intermediate Court that creditors applied for reorganization and pre-reorganization on the grounds that they could not pay off their debts due, obviously lacked solvency but had the value of reorganization. On July 28, the court decided to start the pre-reorganization and appointed the liquidation team of the company as the temporary administrator; On August 4, the investors were publicly recruited; on October 27, the pre-restructuring period was extended to January 28, 2027; on November 4, the above consortium was determined by the evaluation committee.

All can be viewed after purchase
Correlation

It is reported that on July 17, 2026, Yatai Group and its five pharmaceutical subsidiaries received a notice from Changchun Intermediate People's Court. Creditors applied for reorganization and pre-reorganization on the grounds that they could not pay off their due debts and obviously lacked solvency but had the value of reorganization. On July 28, the court decided to start the pre-reorganization and appointed the liquidation team of the company as the temporary administrator. On August 4, the court publicly recruited investors; On October 27, the pre-restructuring period was extended to January 28, 2027; on November 4, the above consortium was determined by the evaluation committee.

2026-11-17 09:46:52

It is reported that on July 17, 2026, Yatai Group and its five pharmaceutical subsidiaries received a notice from Changchun Intermediate People's Court. Creditors applied for reorganization and pre-reorganization on the grounds that they could not pay off their due debts and obviously lacked solvency but had the value of reorganization. On July 28, the court decided to start the pre-reorganization and appointed the liquidation team of the company as the temporary administrator. On August 4, the court publicly recruited investors; On October 27, the pre-restructuring period was extended to January 28, 2027; on November 4, the above consortium was determined by the evaluation committee.